The MELD 3.0 score is an updated version of the Model for End-Stage Liver Disease (MELD), used to assess the severity of chronic liver disease and prioritize patients for liver transplantation. MELD 3.0 refines previous versions by incorporating additional clinical factors to improve its accuracy and equity in predicting 90-day mortality risk for patients with liver disease.

Key Features of MELD 3.0:
New Variables: MELD 3.0 includes additional variables compared to MELD-Na, which primarily used bilirubin, INR, creatinine, sodium, and the need for dialysis.

Albumin: A new addition to reflect the nutritional and inflammatory status of patients.
Sex: Recognizes disparities in outcomes based on biological sex.
Better Predictive Accuracy: The updated formula enhances prediction accuracy for both men and women, addressing previously noted biases (e.g., under-prioritization of women).

Improved Prioritization: The new scoring system aims to ensure fairer organ allocation by better stratifying patients based on true medical urgency.

Application in Transplant Decisions: MELD 3.0 is integrated into organ allocation systems in the United States and other countries, replacing MELD-Na as of January 2023.

Why It Matters:
Equity in Access: MELD 3.0 addresses sex-based disparities in liver transplantation by accounting for physiological differences in creatinine levels between men and women.
Enhanced Outcomes: By refining the risk stratification, MELD 3.0 improves the ability to identify those at the greatest risk of mortality without a transplant.
Formula:
The exact formula for MELD 3.0 has been updated to include the new variables, though the detailed calculation is typically performed by medical systems and software. It uses a logarithmic scale incorporating laboratory values for bilirubin, creatinine, INR, sodium, albumin, and adjustments for dialysis dependency and sex.